Compare Summit Therapeutics Inc (SMMT) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Summit Therapeutics Inc trades at $15.29 (market cap $12.06B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.16. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | SPUS | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $26.98 | $59.51 |
52-Week Low | $12.55 | $46.28 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
SPUS trades at $59.11, up 0.27% today, with a bullish technical signal supported by moving averages. The stock shows strong momentum indicators but an overbought RSI-6. Dividend payments of $0.03 are scheduled for mid-2026, indicating income focus. Recent news highlights the resilience of US dividend strategies amid market concentration.
The outlook remains positive given technical strength and dividend consistency, but overbought conditions near-term suggest caution. Risks include market volatility and reliance on dividend strategy performance. Analyst sentiment is supportive, with institutional interest in dividend-focused equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
